Glen Rock, NJ, United States of America

Allen T Hopper

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2003-2011

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Allen T. Hopper: Innovator in Pharmaceutical Chemistry

Introduction

Allen T. Hopper, hailing from Glen Rock, NJ, is a prominent inventor with a remarkable portfolio of 22 patents. His contributions to the field of pharmaceutical chemistry have paved the way for advancements in medicinal applications, particularly in the development of compounds targeting nicotinic receptors and phosphodiesterase inhibitors.

Latest Patents

Hopper's latest patents focus on innovative compounds that enhance therapeutic efficacy. One notable patent describes heterocyclic compounds and their methods of preparation, which are valuable as ligands for nicotinic receptors. This invention emphasizes the potential applications in treating various neurological disorders. Additionally, he has developed selective phosphodiesterase (PDE4) inhibitors using aryl and heteroaryl pyrazole compounds, which demonstrate improved inhibition over existing treatments like rolipram while maintaining selectivity for other PDE classes.

Career Highlights

Throughout his career, Allen T. Hopper has been associated with notable organizations such as Memory Pharmaceuticals Corporation. This experience has contributed significantly to his expertise in drug discovery and the development of innovative pharmaceutical solutions.

Collaborations

Hopper has collaborated with distinguished professionals in his field, including Ashok Tehim and Ruiping Liu. These collaborations have further enriched his research and innovation endeavors, driving the development of important pharmaceutical compounds.

Conclusion

Allen T. Hopper's dedication to innovation in pharmaceutical chemistry, supported by his extensive patent portfolio and collaborations, underscores his impact on the industry. His work continues to inspire future advancements in medication and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…